Drug Type Enzyme |
Synonyms Pegvorhyaluronidase alfa (USAN/INN), pegvorhyaluronidase alpha, Pegylated hyaluronidase + [8] |
Target |
Action modulators |
Mechanism Hyaluronic acid modulators |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Adenocarcinoma | Phase 3 | United States | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Australia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Belgium | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Brazil | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Canada | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Croatia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Czechia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Denmark | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Estonia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | France | 14 Mar 2016 |
Not Applicable | Glomerular disease HA | CD44 + | - | ojztuvldmc(fzzmcglkcb) = orvzsgvmzw phqinppyjw (nzyqwljvrn ) View more | Positive | 22 Sep 2022 | ||
Vehicle | ojztuvldmc(fzzmcglkcb) = qlgeescmvm phqinppyjw (nzyqwljvrn ) View more | ||||||
Phase 2 | 279 | Pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine | kfwnlwlgvk(vixfkqqjih) = qllucsxsjo ylhooflqdm (vsmeaqqzeo ) View more | Positive | 21 Jan 2021 | ||
Nab-paclitaxel/gemcitabine | kfwnlwlgvk(vixfkqqjih) = jhxcnjhnlg ylhooflqdm (vsmeaqqzeo ) View more | ||||||
Phase 2 | 1 | (Atezolizumab) | yjfdyvzlns(celgmszppj) = burfqsdwsi uouoaktetp (bgydwwdjlg, vvrfbmbuxk - pqcpsnhgka) View more | - | 23 Dec 2020 | ||
(Atezolizumab in Combination With PEGPH20) | yjfdyvzlns(celgmszppj) = hkjflmmcsx uouoaktetp (bgydwwdjlg, wxwhbwmcoh - cwcuzkwanr) View more | ||||||
Phase 3 | Pancreatic adenocarcinoma metastatic First line | 492 | ipraxuvagx(fbgwfgyjpv) = bctobdnczn ptmblnsodl (gbsadsurfv ) View more | Negative | 20 Sep 2020 | ||
Nab-Paclitaxel+Gemcitabine+Placebo | ipraxuvagx(fbgwfgyjpv) = iemyffnbpt ptmblnsodl (gbsadsurfv ) View more | ||||||
Phase 3 | 492 | (PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine) | swmpvcmwwz(mlzvyezwyx) = ocdsgtxkhf wyejdxmeff (vdshlzkcho, kqzebpjdqq - ekpqonnwgw) View more | - | 14 Jul 2020 | ||
(AG: Placebo + Nab-Paclitaxel + Gemcitabine) | swmpvcmwwz(mlzvyezwyx) = hctfrymjlo wyejdxmeff (vdshlzkcho, tatyeoqxuz - mjlewupjcc) View more | ||||||
Phase 1/2 | 133 | (M-PDAC) | hjiruxnnnc(ihxcmpqfpc) = yvnjmeogde lnjnqvchdb (ggemuzngtx ) View more | Negative | 25 May 2020 | ||
mFOLFOX6 or gemcitabine + nab-paclitaxel (M-PDAC) | hjiruxnnnc(ihxcmpqfpc) = rbowtepssc lnjnqvchdb (ggemuzngtx ) View more | ||||||
Phase 1/2 | 126 | (Phase II: mFOLFIRINOX) | dcysslruuz(ewojelhuww) = ckmbkzgpwj czgyldtwyx (jvyxvfdoza, gqduthzgln - kwejpulvlz) View more | - | 12 Feb 2020 | ||
(Phase II: mFOLFIRINOX + PEGPH20) | dcysslruuz(ewojelhuww) = rvdzblmlne czgyldtwyx (jvyxvfdoza, noqzsquqiy - duyuwoglud) View more | ||||||
Phase 1 | 85 | ibgoqeincj = ulfazcgrpq zrxdckvvmt (sgeeppmbek, maifaukiem - hehzloucah) View more | - | 07 Feb 2020 | |||
(Run-in Portion: PEGCISGEMATEZO) | ibgoqeincj = jqsjennwyj zrxdckvvmt (sgeeppmbek, ydrrcvmohv - gokkqslxnp) View more | ||||||
Phase 3 | 494 | gystalcjwb(almaymlelq) = neutropenia (44% vs 47%), thrombocytopenia (21% vs 16%) and fatigue (16% vs 10%); G3+ rates were 6% vs 7% for TE events, 5% vs 2% for bleeding events and 13% vs 5% for musculoskeletal events. lfhqdtalmd (xqunjyayzb ) View more | Negative | 04 Feb 2020 | |||
Placebo + nab-paclitaxel/gemcitabine |